B Lynne Parshall - Net Worth and Insider Trading
B Lynne Parshall Net Worth
The estimated net worth of B Lynne Parshall is at least $4 Million dollars as of 2024-04-27. B Lynne Parshall is the Director of Ionis Pharmaceuticals Inc and owns about 82,588 shares of Ionis Pharmaceuticals Inc (IONS) stock worth over $3 Million. B Lynne Parshall is the Director of Cytokinetics Inc and owns about 10,000 shares of Cytokinetics Inc (CYTK) stock worth over $653,400. B Lynne Parshall is also the Director, 10% Owner of Regulus Therapeutics Inc and owns about 58,746 shares of Regulus Therapeutics Inc (RGLS) stock worth over $142,165. Details can be seen in B Lynne Parshall's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that B Lynne Parshall has not made any transactions after 2023-12-28 and currently still holds the listed stock(s).
Transaction Summary of B Lynne Parshall
B Lynne Parshall Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, B Lynne Parshall owns 6 companies in total, including Akcea Therapeutics Inc (AKCA) , Cytokinetics Inc (CYTK) , and Ionis Pharmaceuticals Inc (IONS) among others .
Click here to see the complete history of B Lynne Parshall’s form 4 insider trades.
Insider Ownership Summary of B Lynne Parshall
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AKCA | Akcea Therapeutics Inc | 2020-10-12 | director |
| CYTK | Cytokinetics Inc | 2022-09-01 | director |
| IONS | Ionis Pharmaceuticals Inc | 2023-12-28 | director & Executive Vice President & CFO |
| RGLS | Regulus Therapeutics Inc | 2012-10-10 | director & 10 percent owner |
| VIAP | VIA Pharmaceuticals Inc | 2006-05-11 | director |
| FHTX | Foghorn Therapeutics Inc | 2022-08-16 | director |
B Lynne Parshall Latest Holdings Summary
B Lynne Parshall currently owns a total of 3 stocks. Among these stocks, B Lynne Parshall owns 82,588 shares of Ionis Pharmaceuticals Inc (IONS) as of December 28, 2023, with a value of $3 Million and a weighting of 81.19%. B Lynne Parshall owns 10,000 shares of Cytokinetics Inc (CYTK) as of September 1, 2022, with a value of $653,400 and a weighting of 15.45%. B Lynne Parshall also owns 58,746 shares of Regulus Therapeutics Inc (RGLS) as of October 10, 2012, with a value of $142,165 and a weighting of 3.36%.
Latest Holdings of B Lynne Parshall
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals Inc | 2023-12-28 | 82,588 | 41.59 | 3,434,835 |
| CYTK | Cytokinetics Inc | 2022-09-01 | 10,000 | 65.34 | 653,400 |
| RGLS | Regulus Therapeutics Inc | 2012-10-10 | 58,746 | 2.42 | 142,165 |
Holding Weightings of B Lynne Parshall
B Lynne Parshall Form 4 Trading Tracker
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 6 transactions in Ionis Pharmaceuticals Inc (IONS) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Ionis Pharmaceuticals Inc is the sale of 117,638 shares on December 28, 2023, which brought B Lynne Parshall around $6 Million.
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 5 transactions in Cytokinetics Inc (CYTK) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Cytokinetics Inc is the sale of 30,296 shares on September 1, 2022, which brought B Lynne Parshall around $2 Million.
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the acquisition of 6,250 shares on October 10, 2012, which cost B Lynne Parshall around $3 Million.
Insider Trading History of B Lynne Parshall
- 1
B Lynne Parshall Trading Performance
GuruFocus tracks the stock performance after each of B Lynne Parshall's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by B Lynne Parshall is 36.87%. GuruFocus also compares B Lynne Parshall's trading performance to market benchmark return within the same time period. The performance of stocks bought by B Lynne Parshall within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how B Lynne Parshall's insider trading performs compared to the benchmark.
Performance of B Lynne Parshall
Average Return
116.63%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.31 | 36.87 | 63.37 | 116.63 | 23.6 | 18.26 |
| Relative Return to S&P 500(%) | 21.99 | 34.11 | 52.54 | 98.48 | 8.25 | 6.21 |
B Lynne Parshall Ownership Network
Ownership Network List of B Lynne Parshall
Ownership Network Relation of B Lynne Parshall
B Lynne Parshall Owned Company Details
What does Akcea Therapeutics Inc do?
Who are the key executives at Akcea Therapeutics Inc?
B Lynne Parshall is the director of Akcea Therapeutics Inc. Other key executives at Akcea Therapeutics Inc include director & Chief Executive Officer Damien Mcdevitt , Chief Medical Officer William T. Andrews , and Chief Financial Officer Michael Dennis Price .
Akcea Therapeutics Inc (AKCA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akcea Therapeutics Inc (AKCA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akcea Therapeutics Inc (AKCA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akcea Therapeutics Inc (AKCA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akcea Therapeutics Inc Insider Transactions
B Lynne Parshall Mailing Address
Above is the net worth, insider trading, and ownership report for B Lynne Parshall. You might contact B Lynne Parshall via mailing address: 2855 Gazelle Court, Carlsbad Ca 92010.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
